Abstract
Outgrowth of a mutated hematopoietic stem/progenitor clone and its descendants, also known as clonal hematopoiesis, has long been considered as either a potential forerunner to hematologic malignancy or as a clinically silent phase in leukemia that antedates symptomatic disease. That definition of clonal hematopoiesis has now been expanded to encompass patients who harbor specific genetic/epigenetic mutations that lead to clonal hematopoiesis of indeterminate potential (CHIP) and, with it, a relatively heightened risk for both myeloid malignancy and atherosclerosis during aging. In this review, we provide contemporary insights into the cellular and molecular basis for CHIP and explore the relationship of CHIP to myeloid malignancy and atherosclerosis. We also discuss emerging strategies to explore CHIP biology and clinical targeting of CHIP related malignancy and cardiovascular disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V (2018) From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res 78:2449–2456. https://doi.org/10.1158/0008-5472.CAN-17-3115
Steensma DP (2019) The clinical challenge of idiopathic cytopenias of undetermined significance (ICUS) and clonal cytopenias of undetermined significance (CCUS). Curr Hematol Malig Rep 14:536–542. https://doi.org/10.1007/s11899-019-00547-3
Hong D, Gupta R, Ancliff P et al (2008) Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319:336–339. https://doi.org/10.1126/science.1150648
Shlush LI, Zandi S, Mitchell A et al (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506:328–333. https://doi.org/10.1038/nature13038
Holyoake TL, Vetrie D (2017) The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129:1595–1606. https://doi.org/10.1182/blood-2016-09-696013
Xie M, Lu C, Wang J et al (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472–1478. https://doi.org/10.1038/nm.3733
Genovese G, Kähler AK, Handsaker RE et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477–2487. https://doi.org/10.1056/nejmoa1409405
Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498. https://doi.org/10.1056/nejmoa1408617
Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377:111–121. https://doi.org/10.1056/nejmoa1701719
Zink F, Stacey SN, Norddahl GL et al (2017) Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130:742–752. https://doi.org/10.1182/blood-2017-02-769869
Abelson S, Collord G, Ng SWK et al (2018) Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559:400–404. https://doi.org/10.1038/s41586-018-0317-6
Desai P, Mencia-Trinchant N, Savenkov O et al (2018) Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med 24:1015–1023. https://doi.org/10.1038/s41591-018-0081-z
King KY, Huang Y, Nakada D, Goodell MA (2020) Environmental influences on clonal hematopoiesis. Exp Hematol 83:66–73. https://doi.org/10.1016/j.exphem.2019.12.005
Chen T, Ueda Y, Dodge JE et al (2003) Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 23:5594–5605. https://doi.org/10.1128/mcb.23.16.5594-5605.2003
Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247–257. https://doi.org/10.1016/S0092-8674(00)81656-6
Sandoval JE, Huang YH, Muise A et al (2019) Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners. J Biol Chem 294:4898–4910. https://doi.org/10.1074/jbc.RA118.006795
Khrabrova DA, Loiko AG, Tolkacheva AA et al (2020) Functional analysis of DNMT3A DNA methyltransferase mutations reported in patients with acute myeloid leukemia. Biomolecules 10:1–16. https://doi.org/10.3390/biom10010008
Challen GA, Sun D, Jeong M et al (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44:23–31. https://doi.org/10.1038/ng.1009
Jeong M, Park HJ, Celik H et al (2018) Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo. Cell Rep 23:1–10. https://doi.org/10.1016/j.celrep.2018.03.025
Hormaechea-Agulla D, Matatall KA, Le DT et al (2021) Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling. Cell Stem Cell 28:1428–1442.e6. https://doi.org/10.1016/j.stem.2021.03.002
Tahiliani M, Koh KP, Shen Y et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935. https://doi.org/10.1126/science.1170116
Li Z, Cai X, Cai CL et al (2011) Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118:4509–4518. https://doi.org/10.1182/blood-2010-12-325241
Abdel-Wahab O, Mullally A, Hedvat C et al (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144–147. https://doi.org/10.1182/blood-2009-03-210039
Abegunde SO, Buckstein R, Wells RA, Rauh MJ (2018) An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis. Exp Hematol 59:60–65. https://doi.org/10.1016/j.exphem.2017.11.002
Cai Z, Kotzin JJ, Ramdas B et al (2018) Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell 23:833–849.e5. https://doi.org/10.1016/j.stem.2018.10.013
Sano S, Oshima K, Wang Y et al (2018) Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J Am Coll Cardiol 71:875–886. https://doi.org/10.1016/j.jacc.2017.12.037
Meisel M, Hinterleitner R, Pacis A et al (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580–584. https://doi.org/10.1038/s41586-018-0125-z
Abdel-Wahab O, Adli M, LaFave LM et al (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180–193. https://doi.org/10.1016/j.ccr.2012.06.032
Fisher CL, Pineault N, Brookes C et al (2010) Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115:38–46. https://doi.org/10.1182/blood-2009-07-230698
Abdel-Wahab O, Gao J, Adli M et al (2013) Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 210:2641–2659. https://doi.org/10.1084/jem.20131141
Wang J, Li Z, He Y et al (2014) Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 123:541–553. https://doi.org/10.1182/blood-2013-05-500272
Yang H, Kurtenbach S, Guo Y et al (2018) Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood 131:328–341. https://doi.org/10.1182/blood-2017-06-789669
Schnittger S, Eder C, Jeromin S et al (2013) ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 27:82–91. https://doi.org/10.1038/leu.2012.262
Dawoud AAZ, Tapper WJ, Cross NCP (2020) Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia 34:2660–2672. https://doi.org/10.1038/s41375-020-0896-8
Morales-Mantilla DE, Huang X, Erice P et al (2020) Cigarette smoke exposure in mice using a whole-body inhalation system. J Vis Exp (164):e61793. https://doi.org/10.3791/61793
Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32:2601–2613. https://doi.org/10.1038/onc.2012.347
Dutta S, Pregartner G, Rücker FG et al (2020) Functional classification of tp53 mutations in acute myeloid leukemia. Cancers 12:1–16. https://doi.org/10.3390/cancers12030637
Kirschner K, Chandra T, Kiselev V et al (2017) Proliferation drives aging-related functional decline in a subpopulation of the hematopoietic stem cell compartment. Cell Rep 19:1503–1511. https://doi.org/10.1016/j.celrep.2017.04.074
Marshall A, Kasturiarachchi J, Datta P et al (2020) Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes. Sci Rep 10:1–13. https://doi.org/10.1038/s41598-020-76218-8
Kuendgen A, Nomdedeu M, Tuechler H et al (2021) Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS. Leukemia 35:835–849. https://doi.org/10.1038/s41375-020-0917-7
Takahashi K, Wang F, Kantarjian H et al (2017) Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18:100–111. https://doi.org/10.1016/S1470-2045(16)30626-X
Bolton KL, Ptashkin RN, Gao T et al (2020) Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 52:1219–1226. https://doi.org/10.1038/s41588-020-00710-0
Bernard E, Nannya Y, Hasserjian RP et al (2020) Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 26:1549–1556. https://doi.org/10.1038/s41591-020-1008-z
Chen S, Gao R, Yao C et al (2018) Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53. Leukemia 32:850–854. https://doi.org/10.1038/leu.2017.325
Sallman DA, McLemore AF, Aldrich AL et al (2020) TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood 136:2812–2823. https://doi.org/10.1182/blood.2020006158
Kleiblova P, Shaltiel IA, Benada J et al (2013) Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol 201:511–521. https://doi.org/10.1083/jcb.201210031
Kahn JD, Miller PG, Silver AJ et al (2018) PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132:1095–1105. https://doi.org/10.1182/blood-2018-05-850339
Hsu JI, Dayaram T, Tovy A et al (2018) PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23:700–713.e6. https://doi.org/10.1016/j.stem.2018.10.004
Gibson CJ, Lindsley RC (2020) Stem cell donors should not be screened for clonal hematopoiesis. Blood Adv 4:789–792. https://doi.org/10.1182/bloodadvances.2019000395
DeZern AE, Gondek LP (2020) Stem cell donors should be screened for CHIP. Blood Adv 4:784–788. https://doi.org/10.1182/bloodadvances.2019000394
Frick M, Chan W, Arends CM et al (2019) Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 37:375–385. https://doi.org/10.1200/JCO.2018.79.2184
Dorsheimer L, Assmus B, Rasper T et al (2019) Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol 4:25–33. https://doi.org/10.1001/jamacardio.2018.3965
Fuster JJ, MacLauchlan S, Zuriaga MA et al (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355:842–847. https://doi.org/10.1126/science.aag1381
Sano S, Oshima K, Wang Y et al (2018) CRISPR-mediated gene editing to assess the roles of TET2 and DNMT3A in clonal hematopoiesis and cardiovascular disease. Circ Res 123:335–341. https://doi.org/10.1161/CIRCRESAHA.118.313225
Sano S, Wang Y, Yura Y et al (2019) JAK2V617F-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic Transl Sci 4:684–697. https://doi.org/10.1016/j.jacbts.2019.05.013
Fidler TP, Xue C, Yalcinkaya M et al (2021) The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592:296–301. https://doi.org/10.1038/s41586-021-03341-5
Abplanalp WT, Cremer S, John D et al (2021) Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ Res 128:216–228. https://doi.org/10.1161/CIRCRESAHA.120.317104
Medzhitov R, Janeway CA (1997) Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9:4–9. https://doi.org/10.1016/S0952-7915(97)80152-5
Murphy AJ, Akhtari M, Tolani S et al (2011) ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 121:4138–4149. https://doi.org/10.1172/JCI57559
Feng Y, Schouteden S, Geenens R et al (2012) Hematopoietic stem/progenitor cell proliferation and differentiation is differentially regulated by high-density and low-density lipoproteins in mice. PLoS One 7:1–12. https://doi.org/10.1371/journal.pone.0047286
Heyde A, Rohde D, McAlpine CS et al (2021) Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell 184:1348–1361.e22. https://doi.org/10.1016/j.cell.2021.01.049
Ventura Ferreira MS, Crysandt M, Ziegler P et al (2017) Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia. Ann Hematol 96:1457–1461. https://doi.org/10.1007/s00277-017-3049-z
Tothova Z, Krill-Burger JM, Popova KD et al (2017) Multiplex CRISPR/Cas9-based genome editing in human hematopoietic stem cells models clonal hematopoiesis and myeloid neoplasia. Cell Stem Cell 21:547–555.e8. https://doi.org/10.1016/j.stem.2017.07.015
Loberg MA, Bell RK, Goodwin LO et al (2019) Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia 33:1635–1649. https://doi.org/10.1038/s41375-018-0368-6
Wang Y, Sano S, Yura Y et al (2020) Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction. JCI Insight 5:1–16. https://doi.org/10.1172/jci.insight.135204
Spyrou N, Papapetrou EP (2021) Studying leukemia stem cell properties and vulnerabilities with human iPSCs. Stem Cell Res 50:1–9. https://doi.org/10.1016/j.scr.2020.102117
Wang T, Pine AR, Kotini AG et al (2021) Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell 28:1–16. https://doi.org/10.1016/j.stem.2021.01.011
Russler-Germain DA, Spencer DH, Young MA et al (2014) The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25:442–454. https://doi.org/10.1016/j.ccr.2014.02.010
Boettcher S, Miller PG, Sharma R et al (2019) A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365:599–604. https://doi.org/10.1126/science.aax3649
Dudgeon C, Shreeram S, Tanoue K et al (2013) Genetic variants and mutations of PPM1D control the response to DNA damage. Cell Cycle 12:2656–2664. https://doi.org/10.4161/cc.25694
Inoue D, Matsumoto M, Nagase R et al (2016) Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. Exp Hematol 44:172–176.e1. https://doi.org/10.1016/j.exphem.2015.11.011
Miles LA, Bowman RL, Merlinsky TR et al (2020) Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587:477–482. https://doi.org/10.1038/s41586-020-2864-x
Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131. https://doi.org/10.1056/nejmoa1707914
Guan Y, Tiwari AD, Phillips JG et al (2021) A therapeutic strategy for preferential targeting of TET2 -mutant and TET dioxygenase–deficient cells in myeloid neoplasms. Blood Cancer Discov 2:146–161. https://doi.org/10.1158/2643-3230.bcd-20-0173
Cimmino L, Dolgalev I, Wang Y et al (2017) Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170:1079–1095.e20. https://doi.org/10.1016/j.cell.2017.07.032
Agathocleous M, Meacham CE, Burgess RJ et al (2017) Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549:476–481. https://doi.org/10.1038/nature23876
Fuster JJ, Zuriaga MA, Zorita V et al (2020) TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep 33:1–9.e5. https://doi.org/10.1016/j.celrep.2020.108326
GarcÃa-Nieto PE, Morrison AJ, Fraser HB (2019) The somatic mutation landscape of the human body. Genome Biol 20(298):1–20. https://doi.org/10.1186/s13059-019-1919-5
Franco I, Helgadottir HT, Moggio A et al (2019) Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type. Genome Biol 20(285):1–22. https://doi.org/10.1186/s13059-019-1892-z
Murai K, Skrupskelyte G, Piedrafita G et al (2018) Epidermal tissue adapts to restrain progenitors carrying clonal p53 mutations. Cell Stem Cell 23:687–699.e8. https://doi.org/10.1016/j.stem.2018.08.017
Fernandez-Antoran D, Piedrafita G, Murai K et al (2019) Outcompeting p53-mutant cells in the normal esophagus by redox manipulation. Cell Stem Cell 25:329–341.e6. https://doi.org/10.1016/j.stem.2019.06.011
Acknowledgments
The Rodrigues laboratory is supported by the Leukemia Cancer Society, Leukaemia Research Appeal for Wales, and the Saudi Arabian Cultural Bureau.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Menendez-Gonzalez, J.B., Rodrigues, N.P. (2022). Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis. In: Ramji, D. (eds) Atherosclerosis. Methods in Molecular Biology, vol 2419. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1924-7_5
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1924-7_5
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1923-0
Online ISBN: 978-1-0716-1924-7
eBook Packages: Springer Protocols